文献速递糖尿病

卡格列净对肾脏和心血管结局的影响按2型糖尿病病程分析:CANVAS项目与CREDENCE试验的汇总分析

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
PubMed 文献 · Diabetes Care · 2024-01-01

本研究为CANVAS项目(N=10,142)与CREDENCE试验(N=4,401)的事后汇总分析,评估卡格列净在不同糖尿病病程间期对心血管和肾脏结局的影响。结果显示卡格列净的获益在各病程间期存在范围,主要不良心血管事件、心血管死亡或心力衰竭住院、需治疗的肾衰竭或血清肌酐翻倍均无异质性。卡格列净减少白蛋白尿进展并增加白蛋白尿消退,在所有糖尿病病程亚组间无交互作用。

要点

  • 卡格列净对主要不良心血管事件、心血管死亡或心衰住院、肾衰竭或肌酐翻倍的获益在各糖尿病病程间期无异质性。
  • 卡格列净减少白蛋白尿进展并增加白蛋白尿消退,在所有糖尿病病程亚组间无交互作用。
  • 研究结果提示,较早使用卡格列净可为2型糖尿病患者带来一致的心肾获益。

核心结论

  • 研究结果提示,较早使用卡格列净可为2型糖尿病患者带来一致的心肾获益。

研究设计与样本

  • CANVAS项目(N=10,142)与CREDENCE试验(N=4,401)的事后汇总分析,按糖尿病病程5年间期评估卡格列净对心血管和肾脏结局的影响,使用Cox比例风险模型计算风险比和95%CI。

主要发现

  • 卡格列净的获益在各糖尿病病程间期存在范围,主要不良心血管事件、心血管死亡或心力衰竭住院、需治疗的肾衰竭或血清肌酐翻倍均无异质性。
  • 卡格列净减少白蛋白尿进展并增加白蛋白尿消退,在所有糖尿病病程亚组间无交互作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study was undertaken because it was unknown whether the duration of type 2 diabetes modifies the effects of sodium-glucose cotransporter 2 inhibitor canagliflozin on cardiovascular (CV) and kidney outcomes. RESEARCH DESIGN AND METHODS: This post hoc analysis of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (N = 10,142) and Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) trial (N = 4,401) evaluated hazard ratios and 95% CIs using Cox proportional hazards for the effects of canagliflozin on CV and kidney outcomes, including progression and regression of albuminuria over 5-year intervals of disease duration. RESULTS: Canagliflozin had ranges of benefit across intervals of diabetes duration, with no heterogeneity for major adverse CV events, CV death or heart failure hospitalization, and kidney failure requiring therapy or doubling serum creatinine. Furthermore, canagliflozin reduced albuminuria progression and increased albuminuria regression with no interaction across all diabetes duration subgroups. CONCLUSIONS: Our findings suggest that earlier treatment with canagliflozin confers consistent cardiorenal benefits to individuals with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Tobe SW, Mavrakanas TA, Bajaj HS, et al. Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials. Diabetes Care. 2024. PMID: 38252809. doi:10.2337/dc23-1450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。